ProStrakan's Rectogesic hit with another delay in US
This article was originally published in Scrip
Executive Summary
The US FDA has hit ProStrakan's troubled Rectogesic (nitroglycerin 0.4% ointment) with complete response letter asking for "additional clinical data" to prove its efficacy for the treatment of pain associated with chronic anal fissures.